Form 144 Filer Information

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

#### NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## **144: Filer Information**

Filer CIK	0001291937
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	
Submission Contact Information	
Name	
Phone	
E-Mail Address	

## 144: Issuer Information

Name of Issuer	Adaptimmune Therapeutics PLC
SEC File Number	001-37368
Address of Issuer	60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE UNITED KINGDOM OX14 4RX
Phone	44 1235 430000
Name of Person for Whose Account the Securities are To Be Sold	Bertrand William C JR

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

**Chief Operating Officer** 

# **144: Securities Information**

Title of the Class of Securities To Be Sold	American Depositary Shares
Name and Address of the Broker	Maxim Group 300 Park Ave 16th Floor New York NY 10022
Number of Shares or Other Units To Be Sold	5584
Aggregate Market Value	3243.00
Number of Shares or Other Units Outstanding	255880000
Approximate Date of Sale	01/17/2025
Name the Securities Exchange	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or

144: Securities To Be Sold		
Title of the Class	American Depositary Shares	
Date you Acquired	01/17/2025	
Nature of Acquisition Transaction	Sell to cover exercise (cashless)	
Name of Person from Whom Acquired	Adaptimmune Therapeutics plc	
Is this a Gift?	Date Donor Acquired	
Amount of Securities Acquired	5584	
Date of Payment	01/17/2025	
Nature of Payment	COMPENSATION	

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	William Bertrand 60 JUBILEE AVENUE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Title of Securities Sold	American Depositary Shares
Date of Sale	01/13/2025
Amount of Securities Sold	9739
Gross Proceeds	5726.00

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	William Bertrand 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Title of Securities Sold	American Depositary Shares
Date of Sale	01/15/2025
Amount of Securities Sold	9803
Gross Proceeds	5635.00

### 144: Remarks and Signature

Remarks

Date of Notice

01/17/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

William Bertrand

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)